Oceanographic Observations in Chilean Coastal Waters Between Valdivia and Concepcion

The physical oceanography of the biologically productive coastal waters of central Chile (36 degrees to 40 degrees S) is relatively unknown. In December 1998 we made a short exploratory cruise between Valdivia (40 degrees S) and Concepcion (37.8 degrees S) taking temperature, salinity, oxygen, and current velocity profiles. Coincident sea surface temperature and color measurements were obtained by satellite. The results showed an area dominated by wind-induced coastal upwelling, river runoff, intrusion of offshore eddies, mixing, and heating. Upwelling centers were found over the shelf at three locations: inshore of Mocha Island, off Valdivia, and off Lavapie Point. At these centers, equatorial subsurface water (ESSW) intrudes into the coastal waters, sometimes affecting the surface waters. Since ESSW has characteristically low-oxygen and high-salinity values, it is easily detected. Off Valdivia, runoff imparts stratification, while farther north, solar heating and reduced mixing may facilitate stratification. In some areas, even strong winds would not destroy the stratification imparted by the advection of buoyancy that occurs during the upwelling process. Strong equatorward currents (\u3e1 m s(-1)) in the form of an upwelling jet were found off Lavapie Point. This is also the location of an intruding anticyclone. Elsewhere, currents were mainly northward but highly variable because of intrusions from offshore eddies. The sea surface temperature and ocean color images show a complex field of onshore and offshore intrusions combined with the effects of mixing on chlorophyll concentrations. The residence time of upwelled water on the shelf is estimated to be less than 1 week

InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers

Antidepressiu; Migranya; Tractament preventiuAntidepresivo; Migraña; Tratamiento preventivoAntidepressant; Migraine; Preventive treatmentBackground There is currently a wide therapeutic arsenal for migraine patients, without a single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national guidelines, previous treatments and personal experiences. Our objective was to evaluate the differences in the use of migraine treatments between neurologists from different countries. Methods This is a multi-centre observational study carried out by neurologists from specialized headache units in seven countries, retrospective with consecutive inclusion of all patients presenting with a migraine diagnosis, over a period of three months. Results A total of 734 patients were recruited but only 600 were considered in the analysis in order to homogenize the patient cohorts from countries: 200 Spain (ES), 100 Italy (IT), 85 Russia (RUS), 80 Germany (DE), 60 Portugal (PT), 45 Poland (PL) and 30 Australia (AU). 85.4 % of patients were women with a mean age of 42.6 ± 11.8 years. Considering previous and current preventive treatment, the order of use was: antidepressants (69.3 %), antiepileptic drugs (54.7 %), beta-blockers and antihypertensive drugs (49.7 %), OnabotulinumtoxinA (44.0 %) and others (36.2 %). Statistically significant differences were found between all pharmacological classes: antidepressants were commonly used in all countries, with the exception of Poland (AU: 76.7 %, IT: 71.0 %, DE: 60.0 %, PL: 31.1 %, PT: 71.7 %, RUS: 70.6 %, ES: 78.5 %; p < 0.0001); antiepileptic drugs were more frequently prescribed in Portugal, Australia and Spain (AU: 73.3 %, IT: 40.0 %, DE: 37.5 %, PL: 48.9 %, PT: 85.0 %, RUS: 29.4 % and ES: 69.0 %; p < 0.0001); beta-blockers and antihypertensive drugs were frequently used in all countries except Italy (AU: 60.0 %, IT: 14.0 %, DE: 53.8 %, PL: 48.9 %, PT: 68.3 %, RUS: 49.4 % and ES: 59.0 %; p < 0.0001); BTX-A were predominately used in Spain, Italy and Australia (AU:56.7 %, IT:58.0 %, DE:20.0 %, PL: 42.2 %, PT: 26.7 %, RUS: 24.7 % and ES: 58.5 %; p < 0.0001) and others were most frequently used in Poland (AU: 0.0 %, IT: 19.0 %, DE: 42.5 %, PL: 95.6 %, PT: 31.7 %, RUS: 3.5 % and ES: 49.5 %; p < 0.0001). If only patients without comorbidities are considered (200/600), statistically differences between countries persist in all preventive treatments. Conclusions There is heterogeneity in the choice of preventive treatment between different countries. Prospective comparative studies of the different oral and subcutaneous alternatives would help to create a global therapeutic algorithm that would guarantee the best option for our patients.This work did not receive any funds

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

© 2018 Moreno et al.The CXCR4/CXCL12 axis has been extensively associated with different types of cancer correlating with higher aggressiveness and metastasis. In diffuse large B-cell lymphoma (DLBCL), the expression of the chemokine receptor CXCR4 is involved in the dissemination of malignant B cells and is a marker of poor prognosis. CXCR7 is a chemokine receptor that binds to the same ligand as CXCR4 and regulates de CXCR4-CXCL12 axis. These findings together with the report of CXCR7 prognostic value in several tumor types, led us to evaluate the expression of CXCR7 in diffuse large B-cell lymphoma biopsies. Here, we describe that CXCR7 receptor is an independent prognostic factor that associates with good clinical outcome. Moreover, the expression of CXCR7 associates with increased survival in CXCR4+ but not in CXCR4- DLBCL patients. Thus, the combined immunohistochemical evaluation of both CXCR7 and CXCR4 expression in DLBCL biopsies may improve their prognostic value as single markers. Finally, we show that CXCR7 overexpression in vitro is able to diminish DLBCL cell survival and increase their sensitivity to antitumor drugs. Hence, further studies on the CXCR7 receptor may establish its role in DLBCL and the molecular mechanisms that modulate CXCR4 activity.This work was supported by Instituto de Salud Carlos III (co-founding from FEDER) [ FIS PI11/00872, RD12/0036/0071, FIS PI14/00450 to J.S., FIS PI15/00378 to R.M., PIE15/00028 to R.M. and J.S., RD12/0036/0069, PS09/01382 to M.G.D, PI15/01393 to M.A, CD13/00074 to V.P.]; Centro de Investigación Biomédica en Red (CIBER) [CB06/01/1031 and Nanomets3 to R.M. and CB16/12/00233 to M.G.D.]; Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) [2014-SGR-1041, 2014PROD0005 to R.M and 2014-SGR-1281 to J.S]; Fundació La Marató TV3 [416/C/2013-2030 to R.M, 100830/31/32 to J.S and M.G.D.]; Josep Carreras Leukaemia Research Institute [P/AG 2014 to R.M.]; the Health Council of Castilla y León (BIO/SA56/13 and BIO/SA78/15 to M.A.); Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) [2017FI_B00680 to A.F.]

Variability of coil inductance measurements inside an interleaving structure

The present article is a continuation of our previous works on the anomalies in the decay rates and the capacitance measurements inside a modified Faraday cage. Here we present the anomalous variations in the measurements of inductance when a coil is placed inside an interleaving structure of metal and organic material. The fluctuation in the inductance values was found to be in the range − 0.007 to 0.018 mH. Additionally, it was observed that the temperature coefficient which was 0.0062 mH/°C initially jumped to two distinct levels, 0.0095 mH/°C and 0.0145 mH/°C, respectively. A multiple factor analysis of our results revealed a very strong correlation (R2 = 95.2%) between the inductance and the combination of the temperature and the relative humidity both measured inside the cage, next to the inductor.DGAPA-UNAM (Mexico) | Ref. IN103522Ministerio de Ciencia e Innovación | Ref. PID2021-128676OB-I0

Falls screening and assessment tools used in acute mental health settings : A review of policies in England and Wales

V. Narayanan, et al, "Falls screening and assessment tools used in acute mental health settings: A review of policies in England and Wales", Physiotherapy, Vol. 102, Issue 2: 178-183, June 2016. © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Objectives: There is an urgent need to improve the care of older people at risk of falls or who experience falls in mental health settings. The aims of this study were to evaluate the individual falls risk assessment tools adopted by National Health Service (NHS) mental health trusts in England and healthcare boards in Wales, to evaluate the comprehensiveness of these tools and to review their predictive validity. Methods: All NHS mental health trusts in England (n = 56) and healthcare boards in Wales (n = 6) were invited to supply their falls policies and other relevant documentation (e.g. local falls audits). In order to check the comprehensiveness of tools listed in policy documents, the risk variables of the tools adopted by the mental health trusts' policies were compared with the 2004 National Institute for Health and Care Excellence (NICE) falls prevention guidelines. A comprehensive analytical literature review was undertaken to evaluate the predictive validity of the tools used in these settings. Results: Falls policies were obtained from 46 mental health trusts. Thirty-five policies met the study inclusion criteria and were included in the analysis. The main falls assessment tools used were the St. Thomas' Risk Assessment Tool in Falling Elderly Inpatients (STRATIFY), Falls Risk Assessment Scale for the Elderly, Morse Falls Scale (MFS) and Falls Risk Assessment Tool (FRAT). On detailed examination, a number of different versions of the FRAT were evident; validated tools had inconsistent predictive validity and none of them had been validated in mental health settings. Conclusions: Falls risk assessment is the most commonly used component of risk prevention strategies, but most policies included unvalidated tools and even well validated tool such as the STRATIFY and the MFS that are reported to have inconsistent predictive accuracy. This raises questions about operational usefulness, as none of these tools have been tested in acute mental health settings. The falls risk assessment tools from only four mental health trusts met all the recommendations of the NICE falls guidelines on multifactorial assessment for prevention of falls. The recent NICE (2013) guidance states that tools predicting risk using numeric scales should no longer be used; however, multifactorial risk assessment and interventions tailored to patient needs is recommended. Trusts will need to update their policies in response to this guidance.Peer reviewedFinal Published versio

An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination

Altres ajuts: EU COST Action CA 17140 to R.M. A grant from La Generalitat de Catalunya (PERIS) [SLT002/16/00433 to J.S.]; a grant from the Generalitat de Catalunya CERCA Programme. The work was also supported by PERIS program from the health department of the Generalitat de Catalunya (SLT006/17/00093) [grated to U.U.] and Fundación Española de Hematología y Hemoterapia (FEHH) [granted to V.P.]. Finally, AV received an ICREA ACADEMIA Award supported by the Catalan Government.Background: current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and extramedullar sites. We developed a protein-based nanoparticle conjugated to the potent antimitotic agent Auristatin E that selectively targets AML blasts because of their CXCR4 receptor overexpression (CXCR4+) as compared to normal cells. The therapeutic rationale is based on the involvement of CXCR4 overexpression in leukemic blast homing and quiescence in the bone marrow, and the association of these leukemic stem cells with minimal residual disease, dissemination, chemotherapy resistance, and lower patient survival. - Methods: monomethyl Auristatin E (MMAE) was conjugated with the CXCR4 targeted protein nanoparticle T22-GFP-H6 produced in E. coli. Nanoconjugate internalization and in vitro cell viability assays were performed in CXCR4+ AML cell lines to analyze the specific antineoplastic activity through the CXCR4 receptor. In addition, a disseminated AML animal model was used to evaluate the anticancer effect of T22-GFP-H6-Auristatin in immunosuppressed NSG mice (n = 10/group). U of Mann-Whitney test was used to consider if differences were significant between groups. - Results: T22-GFP-H6-Auristatin was capable to internalize and exert antineoplastic effects through the CXCR4 receptor in THP-1 and SKM-1 CXCR4+ AML cell lines. In addition, repeated administration of the T22-GFP-H6-Auristatin nanoconjugate (9 doses daily) achieves a potent antineoplastic activity by internalizing specifically in the leukemic cells (luminescent THP-1) to selectively eliminate them. This leads to reduced involvement of leukemic cells in the bone marrow, peripheral blood, liver, and spleen, while avoiding toxicity in normal tissues in a luminescent disseminated AML mouse model. - Conclusions: a novel nanoconjugate for targeted drug delivery of Auristatin reduces significantly the acute myeloid leukemic cell burden in the bone marrow and blood and blocks its dissemination to extramedullar organs in a CXCR4+ AML model. This selective drug delivery approach validates CXCR4+ AML cells as a target for clinical therapy, not only promising to improve the control of leukemic dissemination but also dramatically reducing the severe toxicity of classical AML therapy

Decarbonising the transport and energy sectors: Technical feasibility and socioeconomic impacts in Costa Rica

Compliance with the Paris Agreement requires the transformation of national economies to meet net-zero carbon dioxide emissions by mid-century. To accomplish this, countries need to define long-term decarbonisation strategies with near- and mid-term actions to determine their ideal future scenario while maximizing socioeconomic benefits. This paper describes the process followed to support the creation of the decarbonisation pathway for the transport and energy sectors presented in Costa Rica's National Decarbonisation Plan. We discuss in detail the technological pathway of a deep-decarbonisation future that supports reaching net-zero emissions by 2050. Compared to a business-as-usual (BAU) scenario, our results show that the decarbonisation pathway can lead to emissions' reduction of 87% in the transport and energy sectors by 2050. Energy efficiency, the adoption of electromobility, modal-shift towards public transport and active mobility, as well as reduced demand due to digitalisation and teleworking, are found to be key drivers towards the deep-decarbonisation. These measures combined enable a 25% reduction of primary energy production by 2050. The results highlight that the decarbonisation scenario requires installing 4.4 GW more of renewable power plants by 2050, compared to the BAU scenario (80%). We also show that additional investments for the deep-decarbonisation are compensated with the reduced operating cost. Crucially, we found that the National Decarbonisation Plan results in a lower total discounted cost of about 35% of current Costa Rica's GDP, indicating that a deep decarbonisation is technically feasible and is coupled to socioeconomic benefits

Hospital-based proton therapy implementation during the COVID pandemic: early clinical and research experience in a European academic institution

Introduction A rapid deploy of unexpected early impact of the COVID pandemic in Spain was described in 2020. Oncology practice was revised to facilitate decision-making regarding multimodal therapy for prevalent cancer types amenable to multidisciplinary treatment in which the radiotherapy component searched more efcient options in the setting of the COVID-19 pandemic, minimizing the risks to patients whilst aiming to guarantee cancer outcomes. Methods A novel Proton Beam Therapy (PBT), Unit activity was analyzed in the period of March 2020 to March 2021. Institutional urgent, strict and mandatory clinical care standards for early diagnosis and treatment of COVID-19 infection were stablished in the hospital following national health-authorities’ recommendations. The temporary trends of patients care and research projects proposals were registered. Results 3 out of 14 members of the professional staf involved in the PBR intra-hospital process had a positive test for COVID infection. Also, 4 out of 100 patients had positive tests before initiating PBT, and 7 out of 100 developed positive tests along the weekly mandatory special checkup performed during PBT to all patients. An update of clinical performance at the PBT Unit at CUN Madrid in the initial 500 patients treated with PBT in the period from March 2020 to November 2022 registers a distribution of 131 (26%) pediatric patients, 63 (12%) head and neck cancer and central nervous system neoplasms and 123 (24%) re-irradiation indications. In November 2022, the activity reached a plateau in terms of patients under treatment and the impact of COVID pandemic became sporadic and controlled by minor medical actions. At present, the clinical data are consistent with an academic practice prospectively (NCT05151952). Research projects and scientifc production was adapted to the pandemic evolution and its infuence upon professional time availability. Seven research projects based in public funding were activated in this period and preliminary data on molecular imaging guided proton therapy in brain tumors and post-irradiation patterns of blood biomarkers are reported. Conclusions Hospital-based PBT in European academic institutions was impacted by COVID-19 pandemic, although clinical and research activities were developed and sustained. In the post-pandemic era, the benefts of online learning will shape the future of proton therapy education

Molecularly imprinted polypyrrole based electrochemical sensor for selective determination of 4-ethylphenol

This work describes the development of an electrochemical sensor based on a molecularly imprinted polymer (MIP) for sensitive and selective determination of 4-ethylphenol in wine. The sensor has been built by means of the electrosynthesis of the MIP on a glassy carbon electrode surface using cyclic voltammetry. The electropolymerization has been performed in the presence of 4-ethylphenol and pyrrole as template molecule and functional monomer, respectively. The influence of the molar ratios of template molecules to functional pyrrole monomers and the time needed to remove the template have been optimized taking into account the differential pulse voltammetric response of 4-ethylphenol. Under the optimal experimental conditions the developed MIP/GCE sensor shows good capability of detection (0.2 μM, α = β = 0.05) and reproducibility (3.0%) in the concentration range from 0.2 to 34.8 μM. The influence of possible interfering species in the analytical response has been studied and the sensor has successfully been applied to the determination of 4-ethylphenol in different wine samples.Junta de Castilla y León (BU018G19